Celularity Inc.
Celularity Inc. (CELU)
Overview
Celularity Inc. is a Nasdaq-listed (CELU) cellular and regenerative medicine company, founded in 2016, that develops placental-derived cell therapies targeting cancer, degenerative, and aging-related diseases. The company has about 115 employees and is in significant financial distress: fiscal 2025 revenue fell 51% year over year to $26.55 million, with a net loss of $91.80 million, and the stock has fallen from highs near $2.55 to roughly $1.31, pushing the market capitalization down to about $37.8 million. Celularity has received Nasdaq listing-compliance notices tied to these declines and has been actively restructuring, including selling strategic assets to NexGel in April 2026 to raise capital and entering a manufacturing collaboration with MuseCell Innovations in late August 2026. The company's next earnings report was scheduled for September 29, 2026.
What They Do & How They Make Money
Celularity's science is built on using post-partum human placental tissue — a source normally discarded after birth — as a rich supply of stem and immune cells for therapeutic use. The company organizes its business around three areas: Cell Therapy, developing off-the-shelf, placentally-derived natural killer (NK) cell and T-cell therapies for cancer and infectious disease (its pipeline includes candidates like PDA-001, targeting autoimmune and degenerative conditions); Degenerative Disease, applying placental-derived biomaterials to orthopedic, wound-care, and other degenerative applications; and BioBanking, which stores placental and umbilical cord tissue and cells for families and institutions, generating more stable, recurring storage-fee revenue distinct from the company's clinical-stage therapeutic pipeline. Revenue today comes primarily from BioBanking services and existing biomaterials products, while the larger long-term opportunity — and the primary driver of investor interest — lies in advancing its cell therapy candidates through clinical trials toward regulatory approval, a capital-intensive and currently loss-making endeavor.
Competitive Landscape
In allogeneic cell therapy, Celularity competes against other companies developing off-the-shelf NK-cell and T-cell platforms, including larger, better-funded biotechs pursuing similar cancer immunotherapy approaches. In biobanking, it competes against established cord-blood and tissue banking companies that have built large, trusted family-client bases over many years. In degenerative-disease biomaterials, it faces competition from established regenerative medicine and orthopedic biologics suppliers. Across all three areas, Celularity is a small, financially strained player competing against larger, more capitalized incumbents.
Competitive Position
Celularity's differentiated asset is its placental-tissue sourcing and processing platform, which gives it a genuinely distinct cell-therapy pipeline and a recurring BioBanking revenue stream not tied to clinical trial outcomes. However, the company's overall competitive position is weak and worsening: a 51% revenue decline, a net loss nearly 3.5 times that revenue, Nasdaq compliance concerns, and recent asset sales to raise cash all point to a company under real financial pressure rather than one competing from strength. Its path forward depends on stabilizing its BioBanking and biomaterials revenue base, successfully executing the MuseCell Innovations manufacturing collaboration to reduce costs, and advancing its cell therapy pipeline far enough to attract partnership or licensing capital before its cash position becomes critical.